CA Patent

CA2509233A1 — 2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators

Assigned to Neurogen Corp · Expires 2004-07-01 · 22y expired

What this patent protects

Certain 2-substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activit y in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation …

USPTO Abstract

Certain 2-substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activit y in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided , as are methods for using such ligands for receptor localization studies.</SD OAB>

Drugs covered by this patent

Patent Metadata

Patent number
CA2509233A1
Jurisdiction
CA
Classification
Expires
2004-07-01
Drug substance claim
No
Drug product claim
No
Assignee
Neurogen Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.